Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Holding RIGL?
Track your performance easily
RIGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.48 - $29.82
Previous Close$18.91
Volume189.91K
Average Volume (3M)221.10K
Market Cap
$333.10M
Enterprise Value$332.21M
Total Cash (Recent Filing)$61.11M
Total Debt (Recent Filing)$60.23M
Price to Earnings (P/E)87.3
Beta1.65
Next Earnings
Feb 27, 2025EPS Estimate
$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding17,615,040
10 Day Avg. Volume228,276
30 Day Avg. Volume221,105
Standard Deviation0.27
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-22.78
Price to Sales (P/S)2.12
Price to Cash Flow (P/CF)3.80
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda24.31
Forecast
1Y Price Target
$34.80Price Target Upside84.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Rigel News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRigel plans to advance the study into its expansion phase, aiming to determine the recommended Phase 2 dose and further evaluate the therapeutic potential of R289.
Financial PerformanceRigel reported strong growth across its commercial portfolio, with net sales reaching $38.9 million in 3Q24, a 44% increase compared to $27.1 million in 3Q23.
Strategic PartnershipsRigel announced an exclusive license and supply agreement with Kissei Pharmaceuticals for the development and commercialization of Rezlidhia in Japan, the Republic of Korea, and Taiwan.
Bears Say
Comparative Risk AnalysisAn analysis showed a higher rate of severe and fatal infections in patients using Gavreto compared to those receiving standard care.
Drug Safety ConcernsA new safety signal for Gavreto has been identified, indicating an increased risk of severe infections.
Immune System ImpactThe increased risk of severe infections with Gavreto may be linked to its unintended inhibition of JAK1 and JAK2, which are crucial for immune regulation.
---
Ownership Overview
20.18% Insiders
25.19% Mutual Funds
24.00% Other Institutional Investors
14.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.48 and its highest was $29.82 in the past 12 months.
What is Rigel’s market cap?
Currently, no data Available
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Feb 27, 2025 which is in 69 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Nov 07, 2024. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.058 by $0.642.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is $0.3.
How many shares outstanding does Rigel have?
Rigel has 17,615,040 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $0.7 in its last earnings report, beating expectations of $0.058. Following the earnings report the stock price went up 42.94%.
Which hedge fund is a major shareholder of Rigel?
Among the largest hedge funds holding Rigel’s share is Graham Capital Management, L.P.. It holds Rigel’s shares valued at N/A.
---
Rigel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.80 (84.03% Upside)
$34.80 (84.03% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.89%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q3 2024
0:00 / 0:00
---
RIGL Stock 12 Month Forecast
Average Price Target
$34.80
▲(84.03% Upside)
Technical Analysis
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+76.90%
reiterated a buy rating 10 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +76.90% per trade.
---